CN116887835A - 用于治疗具有左心室辅助装置植入的患者的肺性高血压的方法 - Google Patents

用于治疗具有左心室辅助装置植入的患者的肺性高血压的方法 Download PDF

Info

Publication number
CN116887835A
CN116887835A CN202280016899.9A CN202280016899A CN116887835A CN 116887835 A CN116887835 A CN 116887835A CN 202280016899 A CN202280016899 A CN 202280016899A CN 116887835 A CN116887835 A CN 116887835A
Authority
CN
China
Prior art keywords
day
macitentan
patient
days
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280016899.9A
Other languages
English (en)
Chinese (zh)
Inventor
马克·罗科
莫纳·塞莱伊
卡罗尔·赵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN116887835A publication Critical patent/CN116887835A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/90—Details not provided for in groups A61M60/40, A61M60/50 or A61M60/80
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Mechanical Engineering (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280016899.9A 2021-02-26 2022-02-25 用于治疗具有左心室辅助装置植入的患者的肺性高血压的方法 Pending CN116887835A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154348P 2021-02-26 2021-02-26
US63/154,348 2021-02-26
PCT/EP2022/054742 WO2022180194A1 (en) 2021-02-26 2022-02-25 Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation

Publications (1)

Publication Number Publication Date
CN116887835A true CN116887835A (zh) 2023-10-13

Family

ID=80933151

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280016899.9A Pending CN116887835A (zh) 2021-02-26 2022-02-25 用于治疗具有左心室辅助装置植入的患者的肺性高血压的方法

Country Status (6)

Country Link
US (1) US20240299384A1 (https=)
EP (1) EP4297754A1 (https=)
JP (1) JP2024507905A (https=)
CN (1) CN116887835A (https=)
CA (1) CA3208560A1 (https=)
WO (1) WO2022180194A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693624B (zh) * 2013-06-14 2018-05-18 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
PT3897646T (pt) * 2018-12-21 2024-07-08 Actelion Pharmaceuticals Ltd Macitentano para tratamento de hipertensão arterial pulmonar

Also Published As

Publication number Publication date
WO2022180194A1 (en) 2022-09-01
JP2024507905A (ja) 2024-02-21
US20240299384A1 (en) 2024-09-12
EP4297754A1 (en) 2024-01-03
CA3208560A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CN112218630A (zh) 降低受试者的心血管事件的风险的方法
TWI900606B (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合
JP7002444B2 (ja) 医薬
JP7620758B2 (ja) 肺動脈性肺高血圧症の治療方法
US20240261242A1 (en) Methods of intravenously administering sotalol
CN113795257A (zh) 用于在治疗门脉性肺动脉高血压中使用的马西替坦
CN106029067A (zh) 慢性肾病的发展抑制或改善剂
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
CN116887835A (zh) 用于治疗具有左心室辅助装置植入的患者的肺性高血压的方法
TW202133850A (zh) 用於治療經Ｆｏｎｔａｎ氏手術緩解之患者之肺血管疾病及／或心臟功能異常的醫藥組成物
Uzu et al. Benidipine attenuates glomerular hypertension and reduces albuminuria in patients with metabolic syndrome
EA018442B1 (ru) Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом
WO2024099953A1 (en) Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension
JP4974255B2 (ja) アンジオテンシンｉｉ受容体拮抗剤の配合剤
RIVERA et al. POS-012 RISK FACTORS FOR AKI AND MORTALITY IN COVID-19 IN WESTERN MEXICO
CN121729228A (zh) 在治疗心力衰竭中使用的化合物azd5462
HK40058705A (en) Methods of reducing the risk of cardiovascular events in a subject
WO2022235779A1 (en) Methods of administering terevalefim
Sun et al. Idiopathic pulmonary arterial hypertension and coexisting nephrotic syndrome with minimal change disease
HK40044137A (en) Methods of reducing the risk of cardiovascular events in a subject
HK40003387A (en) Therapeutic compositions for treating pancreatic cancer
CN113332269A (zh) 降低受试者的心血管事件的风险的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination